Anakinra: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), NICE (England) and NYE METODER (Norway) recommended or restricted anakinra, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 23.6 years separate the first record, 8 Nov 2002 at SMC (Scotland), from the most recent, 24 Jun 2026 at HAS (France).
SMC (Scotland) changed its position: not recommended on 8 Nov 2002, recommended by 8 Oct 2018, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for anakinra, 2 submissions were never made — an outcome set by the company rather than the assessor.
The programme is broad: 8 distinct indication wordings are recorded for anakinra by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 19 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess anakinra, on 8 Nov 2002; AOTMIT (Poland) did not open a file until 2 Nov 2021 — an unusually long tail of 19 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 10 years in total.
5 of the 7 agencies here assessed anakinra more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for anakinra.
The full ledger for anakinra reads 9 recommended, 4 not recommended, 2 non-submission and 2 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 30 Mar 2022 | Indication extension | SMR insufficient | source |
| SMC (Scotland) | 13 Dec 2021 | Treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate. | not recommended | source |
| AOTMIT (Poland) | 2 Nov 2021 | programu lekowego „B.33. Leczenie aktywnej postaci reumatoidalnego zapalenia stawów i młodzieńczego idiopatycznego zapal… | recommended conditionally | source |
| NYE METODER (Norway) | 30 May 2021 | Behandling av familiær middelhavsfeber. | introduced | source |
| NICE (England) | 31 Mar 2021 | NICE TA685 | recommended (optimised) | source |
14 further decisions for anakinra, across 5 agencies, are not shown here. They include the most recent record on file, 24 Jun 2026 from HAS (France); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 19 decisions for anakinra from 7 agencies, 2002 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.